Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 12,000 shares of the firm’s stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $116.34, for a total transaction of $1,396,080.00. Following the sale, the director now owns 193,142 shares in the company, valued at approximately $22,470,140.28. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Stryker Corp. (NYSE:SYK) opened at 116.65 on Friday. The stock has a market capitalization of $43.66 billion, a PE ratio of 27.50 and a beta of 0.72. The company’s 50-day moving average is $115.00 and its 200-day moving average is $113.75. Stryker Corp. has a 12 month low of $86.68 and a 12 month high of $123.55.
Stryker Corp. (NYSE:SYK) last released its quarterly earnings results on Thursday, July 21st. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.37 by $0.02. The company had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.79 billion. Stryker Corp. had a net margin of 15.33% and a return on equity of 23.61%. Equities research analysts forecast that Stryker Corp. will post $5.76 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, October 31st. Investors of record on Friday, September 30th will be paid a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a yield of 1.30%. The ex-dividend date of this dividend is Wednesday, September 28th. Stryker Corp.’s payout ratio is 35.85%.
A number of large investors have recently added to or reduced their stakes in the stock. C M Bidwell & Associates Ltd. acquired a new stake in Stryker Corp. during the first quarter worth about $3,489,000. Advisor Partners LLC increased its stake in Stryker Corp. by 52.3% in the first quarter. Advisor Partners LLC now owns 3,700 shares of the medical technology company’s stock worth $397,000 after buying an additional 1,271 shares during the last quarter. Bessemer Group Inc. increased its stake in Stryker Corp. by 0.7% in the first quarter. Bessemer Group Inc. now owns 10,140 shares of the medical technology company’s stock worth $1,088,000 after buying an additional 73 shares during the last quarter. Canandaigua National Bank & Trust Co. increased its stake in shares of Stryker Corp. by 1.4% in the first quarter. Canandaigua National Bank & Trust Co. now owns 7,086 shares of the medical technology company’s stock valued at $760,000 after buying an additional 100 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. purchased a new stake in shares of Stryker Corp. during the first quarter valued at $1,657,000. 75.49% of the stock is currently owned by institutional investors.
Several analysts have recently weighed in on the stock. Piper Jaffray Cos. raised their price objective on shares of Stryker Corp. from $120.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, July 22nd. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $124.00 target price (up previously from $110.00) on shares of Stryker Corp. in a report on Tuesday, July 19th. Brean Capital reaffirmed a “buy” rating and set a $125.00 target price (up previously from $121.00) on shares of Stryker Corp. in a report on Monday, July 25th. Jefferies Group reaffirmed a “hold” rating and set a $120.00 target price (up previously from $113.00) on shares of Stryker Corp. in a report on Monday, July 25th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker Corp. in a report on Sunday, July 24th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $114.91.
About Stryker Corp.
Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.
Receive News & Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related companies with MarketBeat.com's FREE daily email newsletter.